Itulazax (Betula Verrucosa (108))

Betula verrucosa in Itulazax provides controlled exposure to the birch pollen allergen via the sublingual route. This exposure promotes regulatory T‑cell activity and a shift from IgE‑driven responses toward IgG4 production, gradually reducing hypersensitivity and clinical symptoms.

The dosing regimen for Itulazax is individualized. A qualified healthcare professional determines the appropriate dose and titration schedule based on the patient’s age, severity of allergy, and response to therapy. Patients should follow the prescriber’s instructions exactly.

Safety data for Itulazax in pregnancy and lactation are limited. The product’s pregnancy category is unknown, so clinicians should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing women.

To order Itulazax, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Itulazax offers sublingual administration, which can be more convenient than injectable immunotherapy and may have a lower risk of systemic reactions. Compared with other sublingual extracts, its specific Betula verrucosa composition targets birch pollen allergy, providing a focused therapeutic option.

Itulazax should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperatures to maintain potency and stability throughout its shelf life.

Itulazax is administered sublingually. The patient places the prescribed dose under the tongue and holds it for the recommended time before swallowing, allowing direct contact with oral mucosal immune tissue to facilitate tolerance induction.

The most serious risks include systemic allergic reactions such as anaphylaxis, severe oral or facial edema, and asthma exacerbation. Patients should be monitored after the first dose and instructed to seek immediate medical attention if they experience any signs of a severe reaction.

Itulazax is contraindicated in individuals with a known hypersensitivity to Betula verrucosa extract or any excipients in the formulation. Patients with uncontrolled asthma, severe immunodeficiency, or those taking medications that may mask anaphylaxis (e.g., beta‑blockers) should avoid use unless specifically advised by a physician.